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Abstract 
Background: It has been suggested that individuals with metabolic syndrome (MetS) may be prone to developing 
benign prostatic hyperplasia (BPH), but the direction of causality remains uncertain. The objective of this cross-sec-
tional study was to evaluate the association between BPH and MetS in men who were referred to surgery for BPH. We 
were interested in identifying the anthropometric, metabolic, and hormonal factors that potentially influence the risk 
of both conditions.
Methods: The study was conducted on 128 males with BPH and 141 without BPH (the control group). Fasting glu-
cose, insulin, lipid profiles, total and free testosterone, estradiol, sex-hormone binding protein (SHBG), dehydroepian-
drosterone sulfate (DHEA-S), homeostasis model assessment (HOMA-IR) index, and lipid accumulation product (LAP) 
were all evaluated.
Results: The prevalence of MetS was higher in patients with BPH than in the controls (58 vs. 41 %; P = 0.007). In com-
parison to the controls, patients with BPH had higher levels of cholesterol, low density lipoproteins, DHEA-S, insulin, 
and HOMA-IR, but lower levels of high-density lipoproteins (HDL), estradiol, and SHBG. The significant predictors of 
BPH were MetS (OR = 1.961), age (OR = 0.11), HDL (OR = 0.91), insulin (OR = 1.224), SHBG (OR = 0.98), and estradiol 
(OR = 0.978). Waist circumference and LAP inversely correlated with total and free testosterone and SHBG.
Conclusions: Our study confirmed the frequent coexistence of MetS and BPH. This association seems to be a conse-
quence of the MetS-related metabolic derangements, changes in the sex-hormone milieu, and lowered SHBG levels.
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Background
Benign prostatic hyperplasia (BPH) is the most com-
mon urological condition among elderly males, affecting 
approximately half of men over 80  years of age. It usu-
ally begins as a simple micronodular hyperplasia with 
a subsequent macroscopic nodular enlargement that 
may result in bladder outlet obstruction and the devel-
opment of lower urinary tract symptoms (LUTS) [1]. 
Although many inflammatory, hormonal, lifestyle, and 
environmental factors that may predispose to BPH have 
been identified, the molecular and stromal mechanisms 
involved in the pathogenesis of this condition have not 
yet been fully elucidated. It has been suggested that cer-
tain sex-hormone environments—including lower andro-
gen levels and higher estrogen levels—may contribute to 
the development of BPH [2, 3], as estrogens promote the 
androgen effects, leading to increase in prostate weight 
[4]. On the other hand, other studies have shown an 
opposite, positive association between testosterone level 
and the severity of LUTS, [5] or no relationship between 
circulating sex hormones and urological symptoms [6]. 
Much less is known about the association between BPH 
and the level of sex-hormone binding globulin (SHBG); to 
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date, studies have yielded inconsistent results. Although 
some studies have failed to find an association between 
SHBG levels and the incidence of BPH or the severity of 
LUTS [7, 8], other reports have demonstrated that SHBG 
is inversely associated with larger prostate glands [9, 10].
More recently, it has been suggested that individuals 
with metabolic syndrome (MetS) or its individual compo-
nents—including central obesity, hyperinsulinemia, insu-
lin resistance, and dyslipidemia—also may be prone to 
developing BPH and LUTS [3, 11, 12]. On the other hand, 
some earlier studies found no such relationship [13, 14].
The objectives of the current study were (1) to evalu-
ate the association between BPH and MetS, as defined by 
the International Diabetes Federation (IDF) diagnostic 
criteria, and (2) to identify anthropometric, metabolic, 




The study group consisted of males aged 50–75  years 
who had been referred to the university-affiliated Depart-
ment of Urology in Szczecin due to moderate-to-severe 
LUTS, including filling, irritative, voiding, and obstruc-
tive symptoms. Using the standard International Prostate 
Symptom Score (IPSS) tool, a quality of life question-
naire, and prostate imaging, patients were diagnosed; 
those receiving a diagnosis of BPH were referred to 
transurethral resection of the prostate (TURP), accord-
ing to current recommendations and practical guidelines 
[15]. Eligibility criteria were, according to the European 
Association of Urology [16], included in prostate volume 
above 20–80 ml on transrectal ultrasonography and IPSS 
result 8 or more.
The control group consisted of age-matched men who 
had IPSS scores between 0 and 7 and who were neither 
diagnosed nor considered for treatment for BPH. These 
subjects were randomly selected from the local gen-
eral practitioner registers. The exclusion criteria in both 
groups included a body mass index above 35.0  kg/m2, 
malignancy in the past 5 years, heart failure, severe liver 
diseases, and chronic kidney disease. Overall, there were 
128 males with BPH and 141 without BPH who com-
pleted all the study procedures. Informed consent was 
obtained from each patient in the study. The study proto-
col was approved by the Ethics Committee of the Pomer-
anian Medical University in Szczecin and conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki 
(6th revision, 2008).
Measurements
For all study participants, the weight, height, waist cir-
cumference (WC), and sitting blood pressure were 
measured. The body mass index (BMI) was then calcu-
lated from the weight and height. Using automated meth-
ods and commercially available assays, we measured 
fasting glucose, insulin, lipid profile (including triglycer-
ides, total cholesterol and high (HDL) and low-density 
(LDL) lipoproteins), luteinizing hormone (LH), total 
testosterone (reference ranges in men 8–11, 8  nmol/l) 
and free testosterone, estradiol, SHBG, and dehydroe-
piandrosterone sulfate (DHEA-S). Insulin resistance 
was evaluated by the homeostasis model assessment 
(HOMA-IR) index, calculated as blood glucose (mmol/
l−1)  ×  insulin concentration (µIU/ml−1)/22.5  [17]. We 
used the HOMA-IR cut-off of 2.77 to identify subjects 
with insulin resistance [15, 18]. The lipid accumula-
tion product (LAP) was calculated using the following 
equation: LAP  =  (waist circumference in centimeters 
− 65) ×  triglycerides (nmol/l). LAP, an estimate of lipid 
accumulation in adults, has been shown to be a marker of 
metabolic risk and is a useful tool for stratifying the risk 
of unfavorable obesity-related outcomes [19, 20].
MetS was defined using the IDF criteria as the pres-
ence of central obesity (WC  ≥  94  cm) and any two of 
the following components: (1) HDL  <  1.03  mmol/l or 
specific treatment for this lipid abnormality; (2) systolic 
blood pressure ≥ 130, diastolic blood pressure ≥ 85 mm 
Hg, or treatment of previously diagnosed hyperten-
sion; (3) fasting plasma glucose  ≥  5.55  mmol/l or pre-
viously diagnosed type-2 diabetes; and (4) triglyceride 
level  ≥  1.71  mmol/l or specific treatment for this lipid 
abnormality [21].
Statistical analysis
The descriptive statistics included frequency distribu-
tions (number with condition and percentage) for cat-
egorical variables and means, standard deviation (SD), 
and range for continuous variables. Differences among 
groups were evaluated by an independent t-test or non-
parametric Mann–Whitney U-test for continuous vari-
ables, and by Chi-square test with Yates’ correction for 
dichotomous variables. Univariate and multiple regres-
sion analyses were used to evaluate the independent pre-
dictors of MetS and BPH. The relationship between pairs 
of quantitative variables was represented using Spear-
man’s rank correlation coefficient. Data were considered 
to be significant at P < 0.05.
Results
The baseline anthropometric, metabolic, and hormo-
nal characteristics of the study population are shown in 
Table  1. Compared to the controls, patients with BPH 
were of similar age and had similar BMI, WC, and LAP 
values; had higher levels of total cholesterol and its LDL 
fraction; but had significantly lower HDL cholesterol. 
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They also had significantly higher fasting insulin concen-
tration and calculated HOMA-IR value. However, when 
we excluded cases with overt diabetes and those taking 
hypoglycemic treatments, the percentage of subjects with 
HOMA-IR > 2.77 was higher in men without BPH than 
in those with BPH (62 vs. 45 %; P = 0.014). In both men 
with BPH and those without it, the mean total and free 
testosterone levels were below the reference ranges, but 
comparable between the groups.
The subjects with BPH had higher DHEA-S and LH but 
lower estradiol and SHBG. In both groups, there were 
high prevalences of overweight or obesity (BMI above 
25.0  kg/m2) and of abdominal obesity (waist circumfer-
ence > 94 cm). The overall prevalence of overweight in all 
the males participating in the study was 72 %; the value 
was similar for abdominal obesity. Importantly, despite 
the similar frequency in both groups of each of the indi-
vidual components of MetS, the prevalence of MetS was 
significantly higher in patients with BPH (58 vs. 41  %; 
p = 0.007).
As expected, when we analyzed the patients with BPH 
in subgroups with and without MetS (Table 2), those with 
MetS showed significantly higher BMI, WC, LAP, insu-
lin concentration, and HOMA-IR, as well as higher fre-
quencies of the majority of individual MetS components. 
Despite similar frequencies in both groups of the subjects 
with HDL cholesterol levels below 40  mg/dl, patients 
with MetS had significantly lower mean HDL levels. On 
the other hand, they had lower SHBG and total (though 
not free) testosterone. Moreover, in the subgroup with 
MetS, as many as 88  % of subjects were overweight or 
obese.
Table 1 Baseline characteristics of study participants
a or specific treatment for previously diagnosed condition
Continuous variables BPH (n = 128) Controls (n = 141) P
Mean SD Range Mean SD Range
Age (years) 65.76 6.47 52–77 63.66 5.64 50–74 0.081
Weight (kg) 81.37 11.36 61.5–115 81.78 10.20 54–108 0.684
Height (m) 1.73 0.07 1.53–1.98 1.74 0.05 1.58–1.88 0.117
Body mass index (kg/m2) 27.05 3.27 18.7–34.7 26.78 2.90 20.0–34.7 0.724
Waist (m) 0.98 0.08 0.79–1.20 0.99 0.086 0.75–1.18 0.492
LAP 56.24 35.90 11.4–296.7 51.98 38.66 7.3–234.9 0.350
Cholesterol (mmol/l) 5.68 1.55 2.16–10.76 5.00 1.57 2.17–9.13 0.001
HDL (mmol/l) 0.92 0.27 0.54–1.94 1.32 0.35 0.50–2.45 0.001
LDL (mmol/l) 3.67 1.49 0.58–8.84 3.35 1.50 0.47–10.49 0.019
Triglycerides (mmol/l) 1.64 0.75 0.66–5.44 1.49 0.84 0.43–4.53 0.132
Glucose (mmol/l) 5.85 0.97 4.27–10.21 6.02 1.20 2.93–10.70 0.489
Insulin (pmol/l) 104.10 43.62 2.64–454.92 81.06 37.32 13.98–185.70 0.041
HOMA-IR 5.00 5.85 0.1–26.28 3.64 1.91 0.10–8.85 0.028
Total testosterone (nmol/l) 14.35 6.45 0.35–29.26 13.83 5.96 0.35–34.08 0.205
Free testosterone (pmol/l) 382.93 250.77 3.09–1272.47 373.92 199.84 36.75–1094.19 0.746
Estradiol (pmol/l) 106.06 75.59 21.92–421.80 146.91 83.96 36.16–441.25 0.001
DHEA-S (μmol/l) 3.34 1.98 0.33–9.34 3.94 2.44 0.03–12.51 0.026
SHBG (nmol/l) 38.17 18.83 2.58–98.0 48.32 25.62 4.93–128.0 0.001
LH (mIU/ml) 10.74 7.16 0.70–67.98 8.04 4.04 1.08–33.09 0.001
Categorical variables BPH (n = 128) Controls (n = 141) P
n % n %
Waist > 94 cm 89 69 104 74 0.489
BMI > 25.0 kg/m2 103 73 91 70 0.717
Blood glucose > 5.55 mmol/la 77 60 93 66 0.376
HDL < 1.03 mmol/la 46 36 56 40 0.332
Triglycerides > 1.71 mmol/la 74 58 58 41 0.013
Blood pressure > 130/85 mm Hga 76 59 81 57 0.844
Metabolic syndrome 74 58 58 41 0.007
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In both study groups combined, age, insulin, and 
LH were associated with an increased risk of BPH, and 
SHBG, estradiol, and HDL with a decreased risk of BPH 
(Table  3). Importantly, MetS was a robust predictor of 
BPH (OR  =  1.961; 95  % CI 1.207–3.186; P  =  0.009). 
However, when we included MetS in the regression mod-
els, together with BMI, age, and LAP as covariates, the 
association between BPH and MetS was not significant. 
The presence of BPH was positively associated with LH 
(β  =  0.231; P  =  0.001), free testosterone (β  =  0.257; 
P = 0.009), and insulin (β = 0.148; P = 0.025) and neg-
atively with SHBG (β  =  −0.266; P  =  0.001), estradiol 
(β  =  −0.227; P  =  0.003), and DHEA-S (β  =  −0.162; 
P = 0.030).
The correlations between anthropometric measure-
ments, LAP, lipid profiles, and sex hormones in patients 
with BPH and MetS are shown in Table 4. Both waist cir-
cumference and the LAP index are inversely correlated 
with total and free testosterone and SHBG. Total cho-
lesterol and LDL correlated positively with SHBG, while 
triglycerides correlated negatively with total testosterone 
and were closely significant with free testosterone. The 
association between HDL and SHBG bordered on a sta-
tistically significant value (P = 0.051).
Discussion
In this cross-sectional study, we found a high prevalence 
of MetS and its individual components among patients 
with BPH who were referred for TURP. In these cases, 
we found that age and levels of HDL cholesterol, fast-
ing insulin, SHBG, LH, DHEA-S, and estradiol were sig-
nificantly associated with BPH. Additionally, MetS was a 
robust single predictor of BPH. The latter finding is con-
sistent with many previous reports suggesting that an 
association between BPH and MetS may be plausible [11, 
12, 22–25], although it is not yet fully understood.
Recently, Vignozzi et  al. [26] proposed an interest-
ing three-hit hypothesis on the development of BPH, 
which may also be helpful in understating the mutual 
relationship between BPH and MetS. According to this 
Table 2 Anthropometric, metabolic and  hormonal characteristics of  subjects with  and without  metabolic syndrome 
(patients with BPH)
Continuous variables Metabolic syndrome (n = 74) Without metabolic syndrome (n = 54) P
Mean SD Range Mean SD Range
Age (years) 65.68 6.29 55–77 65.89 6.88 55–77 0.912
Weight (kg) 85.59 10.55 64–115 75.37 9.71 51.5–98 0.001
Height (m) 1.73 0.074 1.54–1.98 1.74 0.071 1.53–1.90 0.996
Body mass index (kg/m2) 28.47 2.87 23.5–34.7 25.03 2.72 18.7–34.6 0.001
LAP 70.97 39.48 20.2–296.7 36.25 15.91 11.4–89.9 0.001
Cholesterol (mmol/l) 4.80 1.48 2.17–9.13 5.26 1.66 3.08–11.76 0.121
LDL (mmol/l) 3.14 1.36 0.47–7.43 3.63 1.65 1.01–10.48 0.112
Insulin (pmol/l) 116.82 105.60 11.22–454.80 93.30 101.64 2.64–423.00 0.272
HOMA-IR 5.13 3.63 0.48–26.28 3.99 2.90 0.1–22.47 0.043
Total testosterone (nmol/l) 13.31 6.48 1.04–28.43 15.71 6.24 0.35–29.12 0.020
Free testosterone (pmol/l) 354.92 236.38 0.35–1274.47 420.65 266.26 3.12–1177.27 0.151
Estradiol (pmol/l) 95.08 70.45 22.25–421.80 120.30 80.21 21.92–321.95 0.090
DHEA-S (μmol/l) 3.47 2.12 0.35–9.34 3.12 1.76 0.33–7.19 0.501
SHBG (nmol/l) 35.39 19.75 2.74–98.0 41.89 17.02 2.58–90.3 0.012
LH (mIU/ml) 11.38 8.61 0.70–67.98 9.89 4.52 1.57–23.0 0.211
Table 3 Prediction of prevalent BPH by age and metabolic 
and hormonal factors
OR odds ratio
OR 95 % CI P value
Age (years) 1.110 1.050; 1.174 0.001
Body mass index (kg/m2) 1.032 0.420; 2.485 0.944
Waist (m) 0.974 0.884; 1.074 0.598
LAP 0.970 0.921; 1.021 0.243
HDL (mmol/l) 0.910 0.874; 0.948 0.001
LDL (mmol/l) 1.006 0.976; 1.038 0.688
Triglycerides (mmol/l) 1.013 0.991; 1.035 0.247
Insulin (pmol/l)) 1.224 1.089; 1.375 0.001
LH (mIU/ml) 1.204 1.091; 1.329 0.001
SHBG (nmol/l) 0.980 0.961; 0.999 0.035
Estradiol (pmol/l) 0.978 0.960; 0.997 0.023
Total testosterone (nmol/l) 1.154 0.938; 1.419 0.176
Free testosterone (pmol/l) 0.999 0.993; 1.004 0.703
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hypothesis, an overt or subclinical inflammation (first 
hit) could be autosustained or overlapped by metabolic 
alternations (second hit) and changes in sex-hormone 
levels (third hit). The combined effects of these may 
result in overexpression of toll-like receptors, transfor-
mation of prostatic cells into antigen-presenting cells, 
and up-regulation of growth factors (andromedins), lead-
ing to prostate enlargement. Among hormonal determi-
nants of BPH, the majority of studies have reported sex 
steroid imbalances between total or free testosterone, 
dihydrotestosterone, estrogen, and progesterone levels 
[2–7], although their circulating levels did not necessarily 
reflect the causal relationship with prostatic volume and 
severity of LUTS.
However, meta-analysis [27] of epidemiological evi-
dences between MetS and LUTS secondary to benign 
prostatic hyperplasia did not demonstrate significant dif-
ferences of IPSS, IPSS-voiding and IPSS-storage by men 
with or without MetS. Presence of MetS was not signifi-
cantly associated with moderate-to-severe LUTS (odds 
ratio  =  1.13; P  =  0.53) and only altered serum triglycer-
ides and diabetes were associated with this risk.
In addition to these sex-steroid derangements, our 
results suggest that they may be also extended by 
changes in circulating DHEA-S and SHBG. Only a few 
studies in the literature have evaluated SHBG in patients 
with BPH, and the results have been inconsistent [7–10]. 
In our series, SHBG concentration was negatively asso-
ciated with the prevalence of BPH. Moreover, in com-
parison to the controls, in cases with BPH there were 
significantly higher levels of DHEA-S and lower levels 
of SHBG. However, the clinical usefulness of SHBG as a 
marker of BPH risk seems uncertain, because its serum 
concentration, like testosterone, is greatly influenced by 
aging and coexisting obesity [28]. Aside from BPH, it 
also has been postulated that low SHBG concentrations 
might be the primary determinant of the incidence of 
MetS [29]. Indeed, a similar conclusion is suggested by 
our study. We observed lower SHBG levels in subjects 
with BPH and coexisting MetS than in those without 
MetS; however, SHBG negatively correlated with BMI, 
LAP, and waist circumference, suggesting that its low 
concentration may be influenced by increased body size, 
unfavorable fat distribution, and lipid accumulation. 
This, in turn, may support the third hit in the concept of 
metabolic alternations in the pathogenesis of BPH [26]. 
Accordingly, numerous observational data indicate a 
close link between central obesity and an increased risk 
of BPH. Giovannucci et al. [30] studied more than 25,000 
men and determined that men with WC > 109 cm were 
100 % more likely to present LUTS and 38 % more likely 
to require surgery for BPH, as compared to those with 
waist circumferences < 109 cm. Likewise, data from the 
National Health and Nutrition Examination Survey III 
(NHANES III) showed an association between waist 
circumference and LUTS, suggesting that progressive 
prostate enlargement in obese men could induce the 
occurrence of urinary symptoms [2].
Waist circumference, a major component of MetS, is a 
surrogate measure of visceral adipose tissue, the accumu-
lation of which is associated with a cluster of metabolic 
abnormalities, including impaired glucose tolerance, 
insulin resistance, hypertension, and unfavorable lipid 
profiles, all of which are risk factors for type-2 diabetes 
and cardiovascular disease. LAP, calculated from WC 
and serum triglyceride levels, possesses similar diagnos-
tic and predictive value [19, 20, 31]. Unexpectedly in this 
study, neither BMI nor waist circumference were deter-
minants of the prevalence of BPH; however, among the 
studied men with and without BPH, we found a high pro-
portion of men who were obese or centrally obese (72 %), 
which is likely to have had an impact on our results.
Table 4 Correlations between anthropometric measurements, LAP, lipid profiles and sex hormones in patients with BPH 
and MetS
Significant correlations are shown in italics





SHBG (nmol/l) DHEA-S (μmol/l) Estradiol (pmol/l)
R P R P R P R P R P
BMI (kg/m2) −0.114 0.339 −0.095 0.422 −0.221 0.063 0.035 0.769 0.014 0.907
Waist (m) −0.283 0.016 −0.248 0.033 −0.272 0.021 −0.023 0.849 −0.086 0.481
LAP −0.361 0.002 −0.286 0.014 −0.283 0.016 0.132 0.269 −0.149 0.217
Total cholesterol (mmol/l) −0.072 0.548 0.016 0.895 −0.123 0.302 0.295 0.012 −0.130 0.285
LDL (mmol/l) −0.038 0.752 0.102 0.392 −0.117 0.329 0.280 0.017 −0.119 0.327
HDL (mmol/l) 0.194 0.103 0.037 0.755 0.231 0.051 0.024 0.842 0.025 0.839
Triglycerides (mmol/l) −0.272 0.021 −0.210 0.075 −0.201 0.090 0.155 0.193 −0.101 0.404
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Among other metabolic alternations in males with 
BPH, we observed higher levels of total and LDL cho-
lesterol, lower HDL cholesterol, and the higher preva-
lence of increased triglycerides above 1.71  mmol/l than 
in those without BPH. Moreover, these subjects also had 
significantly higher insulin levels and HOMA-IR values. 
From previous studies, it can be determined that MetS—
and in particular abnormal lipid profiles including hyper-
triglyceridemia, low HDL cholesterol, and up-regulation 
of LDL cholesterol—could induce or maintain an inflam-
matory state within the prostate [26, 32, 33]. This process 
could be exacerbated by changes in sex-hormone levels 
(as observed in our study), such as relative hyperestro-
genism, decreases in SHBG levels, and androgen defi-
ciency—that is, medical conditions commonly associated 
with MetS, and in particular with abdominal obesity. In 
addition, subjects with excess visceral fat are often prone 
to developing insulin resistance which, in turn, may be an 
independent risk factor for BPH [34–36]. Hence, obese, 
dyslipidemic, and aged males are at risk for MetS, whose 
components are important determinants of prostate 
enlargement [7, 11] as well as of other abdominal obesity-
related comorbidities, including cardiovascular disease, 
obstructive sleep apnea, and nonalcoholic fatty liver dis-
ease [37].
Our study had some limitations. First, due its obser-
vational nature, the associations observed between 
MetS and BPH may not be causal, on account of some 
unknown confounding or reverse causality. Second, 
there was an overexpression in our sample of overweight 
or obese subjects, which likely overestimated the true 
prevalence of MetS. Therefore, our results may not apply 
to the general population of men aged over 50—in par-
ticular to normal weight and underweight individuals. 
Finally, we did not collect data on diet, smoking, or alco-
hol consumption—i.e., on the modifiable independent 
factors that can significantly influence the risks of MetS 
and BPH.
In conclusion, our study confirmed the frequent coex-
istence of MetS and BPH. This association seems to be 
a consequence of the MetS-related changes in the sex-
hormone milieu and metabolic derangements. Therefore, 
as obesity, diet (excess consumption of alcohol, red meat, 
and fat), and a sedentary lifestyle strongly predispose to 
the development of BPH [4, 38], the broad promotion of 
a healthy lifestyle and of healthy dietary patterns may be 
an important tool in both the prevention and treatment 
of this condition.
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